Sugemalimab and Chemotherapy

DRUG3 trials

Sponsors

Hunan Cancer Hospital, Peking Union Medical College, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Carcinoma, Non-Small-Cell LungEsophageal Squamous Cell Carcinoma (ESCC)NSCLC

Phase 2

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

RecruitingNCT05940532

Hunan Cancer HospitalCarcinoma, Non-Small-Cell Lung

Start: 2023-06-14End: 2026-12-31Target: 41Updated: 2023-07-11

Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC

Active, not recruitingNCT07711470

Cancer Institute and Hospital, Chinese Academy of Medical SciencesEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2026-07-01End: 2029-07-31Target: 140Updated: 2026-07-17

Unknown Phase

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

RecruitingNCT07247227

Peking Union Medical CollegeNSCLC

Start: 2023-10-10End: 2027-05-31Target: 150Updated: 2025-11-25